Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1992;1(5):309–312. doi: 10.1155/S0962935192000450

Comparison of the C-mediating killing activity and C-activating properties of mouse monoclonal and polyclonal antibodies against Trypanosoma cruzi

T L Kipnis 1,✉, D V Tambourgi 1, M J M Alves 2, W Dias da Silva 3
PMCID: PMC2365359  PMID: 18475476

Abstract

A Mouse polyclonal antiserum against Trypanosoma cruzi or its IgG and IgM fractions and five monoclonal antibodies (two IgM, two IgG1 and one IgG2a) recognize and combine with membrane components of trypomastigote forms of the parasite as revealed by immunofluorescence. Although all these antibodies sensitize trypomastigotes and prepare them to activate the complement (C) system, as measured by consumption of total C, C4, B and C3, only the polyclonal antiserum or its IgG, IgM and Fabμ fragments were able to induce trypanosome lysis by the alternative C pathway.

Full Text

The Full Text of this article is available as a PDF (385.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alves M. J., Abuin G., Kuwajima V. Y., Colli W. Partial inhibition of trypomastigote entry into cultured mammalian cells by monoclonal antibodies against a surface glycoprotein of Trypanosoma cruzi. Mol Biochem Parasitol. 1986 Oct;21(1):75–82. doi: 10.1016/0166-6851(86)90081-2. [DOI] [PubMed] [Google Scholar]
  2. Fujita T., Gigli I., Nussenzweig V. Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med. 1978 Oct 1;148(4):1044–1051. doi: 10.1084/jem.148.4.1044. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gorski J. P., Hugli T. E., Müller-Eberhard H. J. C4a: the third anaphylatoxin of the human complement system. Proc Natl Acad Sci U S A. 1979 Oct;76(10):5299–5302. doi: 10.1073/pnas.76.10.5299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Joiner K. A., daSilva W. D., Rimoldi M. T., Hammer C. H., Sher A., Kipnis T. L. Biochemical characterization of a factor produced by trypomastigotes of Trypanosoma cruzi that accelerates the decay of complement C3 convertases. J Biol Chem. 1988 Aug 15;263(23):11327–11335. [PubMed] [Google Scholar]
  5. Kipnis T. L., David J. R., Alper C. A., Sher A., da Silva W. D. Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages. Proc Natl Acad Sci U S A. 1981 Jan;78(1):602–605. doi: 10.1073/pnas.78.1.602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kipnis T. L., Krettli A. U., Dias da Silva W. Transformation of trypomastigote forms of Trypanosoma cruzi into activators of alternative complement pathway by immune IgG fragments. Scand J Immunol. 1985 Aug;22(2):217–226. doi: 10.1111/j.1365-3083.1985.tb01874.x. [DOI] [PubMed] [Google Scholar]
  7. Kipnis T. L., Sucupira M., da Silva W. D. Transformation of Trypanosoma cruzi trypomastigote bloodstream forms by immune IgM and its Fab mu fragment into activators of the alternative complement pathway. Braz J Med Biol Res. 1987;20(1):105–114. [PubMed] [Google Scholar]
  8. Kipnis T. L., Tambourgi D. V., Sucupira M., Dias-da-Silva W. Effect of Trypanosoma cruzi membrane components on the formation of the classical pathway C3 convertase. Braz J Med Biol Res. 1986;19(2):271–278. [PubMed] [Google Scholar]
  9. Krettli A. U., Brener Z. Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies. J Immunol. 1982 May;128(5):2009–2012. [PubMed] [Google Scholar]
  10. Lima-Martins M. V., Sanchez G. A., Krettli A. U., Brener Z. Antibody-dependent cell cytotoxicity against Trypanosoma cruzi is only mediated by protective antibodies. Parasite Immunol. 1985 Jul;7(4):367–376. doi: 10.1111/j.1365-3024.1985.tb00083.x. [DOI] [PubMed] [Google Scholar]
  11. Pangburn M. K., Schreiber R. D., Müller-Eberhard H. J. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med. 1977 Jul 1;146(1):257–270. doi: 10.1084/jem.146.1.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Rey-Campos J., Rubinstein P., Rodriguez de Cordoba S. A physical map of the human regulator of complement activation gene cluster linking the complement genes CR1, CR2, DAF, and C4BP. J Exp Med. 1988 Feb 1;167(2):664–669. doi: 10.1084/jem.167.2.664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rimoldi M. T., Sher A., Heiny S., Lituchy A., Hammer C. H., Joiner K. Developmentally regulated expression by Trypanosoma cruzi of molecules that accelerate the decay of complement C3 convertases. Proc Natl Acad Sci U S A. 1988 Jan;85(1):193–197. doi: 10.1073/pnas.85.1.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Seya T., Ballard L. L., Bora N. S., Kumar V., Cui W., Atkinson J. P. Distribution of membrane cofactor protein of complement on human peripheral blood cells. An altered form is found on granulocytes. Eur J Immunol. 1988 Aug;18(8):1289–1294. doi: 10.1002/eji.1830180821. [DOI] [PubMed] [Google Scholar]
  15. Stefani M. M., Takehara H. A., Mota I. Isotype of antibodies responsible for immune lysis in Trypanosoma cruzi infected mice. Immunol Lett. 1983;7(2):91–97. doi: 10.1016/0165-2478(83)90040-8. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES